endpoints· 12d ago

GSK walks away from Alector pact as immuno-neurology bet fizzles

July 9, 2026read original ↗

After two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments.

July 9, 2026 06:51 AM EDT DealsPharma GSK walks away from Alector pact as immuno-neurology bet fizzles Ayisha Sharma News Reporter After two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

78 words · extracted 12d agoread original ↗

🔗 mentioned in this article

no entities indexed yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?